In these very difficult and uncertain time for us all in the Duchenne community, we want to reassure you that we are doing everything we can to stay on top of the situation as it develops.  

We are conscious that this is a very difficult and uncertain time for us all in the Duchenne community, and we want to reassure you that we are doing everything we can to stay on top of the situation as it develops.  
 

Since 2018, the DMD Hub and Duchenne UK have invested £108,324 to fund two key roles at Leeds Teaching Hospital – a Neuromuscular Coordinator, Nadia Khan and a Neuromuscular Clinical Research Fellow, Cristina Martoz Lozano. We are pleased to share with you an update from DMD Hub site Leeds Teaching Hospital.

Duchenne UK is pleased to announce that TAMDMD, the Tamoxifen trial, led by Professor Dirk Fischer, has now been fully recruited for the main group of patients.

This means that in 12 months, these patients will have completed their 48 weeks of treatment and results of the trial can be expected in Spring 2021.

The Phase 1 Open Label Extension and Phase 2 Clinical Trial into Suvodirsen has been terminated on the basis of interim data.

We are very pleased to be able to share with you our first ever DMD Hub Impact Report. The report details all the incredible achievements and progress we have made to expand clinical trial capacity since 2014.

The Phase I/II Extension and the Phase I/III Clinical trial into Roche RO7239361 has been terminated, on the basis of interim data.